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b-2 Adrenoceptor genetic variation is associated with genetic predis-
position to essential hypertension: The Bergen Blood Pressure Study. We
tested the hypothesis that genetic variation in the b-2 adrenoceptor gene
is associated with a genetic predisposition to hypertension. Offspring of
two hypertensive parents were compared with offspring of two normoten-
sive parents. The subjects were participants of the Bergen Blood Pressure
Study, where couples were recruited in 1963 to 1964 and re-examined in
1990. We studied offspring of those couples in which both partners were
either hypertensive or normotensive in both examinations. Twenty-three
hypertensive and 22 normotensive families met the inclusion criteria.
DNA samples from the first born of hypertensive family-history offspring
and normotensive family-history offspring were analyzed. We used mul-
tiplex sequencing and specifically examined the promoter and the N-
terminal portion of the b-2 adrenoceptor gene. We found four genetic
variants: at position 247, a C3T substitution in the 59 leader cistron
causing an Arg3Cys exchange, at 220, a T3C substitution, at 146 an
A3G substitution leading to an Arg163Gly exchange, and at 179, a
C3G substitution leading to a Gln273Glu exchange. The frequency of
the Arg16 allele was significantly higher in the hypertensive family-history
offspring compared to normotensive family-history offspring (58% vs.
28%, P , 0.011). We constructed haplotypes for the four intragenic
variants and found significant linkage dysequilibrium. In particular, the 59
leader cistron mutant with the wild type alleles at the other loci was
significantly more frequent in offspring of hypertensive parents, compared
to offspring of normotensive parents. We also performed a relative risk
analysis comparing the Gly/Gly, Arg/Gly, and Arg/Arg alleles, which
implicated the Arg-containing allele. Finally, we analyzed the effect of
genotype on blood pressure in the offspring. We found a signficant
step-wise effect for all four polymorphisms examined. Our data suggest
that the Arg variant of the Arg3Gly exchange is associated with parental
hypertension and higher blood pressure values in this northern European
population.
Heritable effects on blood pressure have been known since the
family studies of Weitz [1], who concluded that hypertension is
inherited in an autosomal-dominant fashion. Weitz erred, but
only in terms of his interpretation of essential hypertension as a
monogenic disease. Pickering’s group showed conclusively by
means of extensive family studies that essential hypertension is a
multifactorial disorder [2]. In offspring studies, the definition of
family blood pressure histories is essential. Blood pressure is a
quantitative variable by its nature, and displays considerable
variation with time, short-range (diurnal) as well as long-range
(age). Thus, classification to a dichotomous variable results in a
considerable loss of information and risk of misclassification.
Considering methodological aspects in offspring studies, Watt [3]
suggested three important guidelines in family studies: (1) sam-
pling should begin with the parents, rather than the offspring; (2)
an attempt should be made to measure or take account of both
parental blood pressure levels; and (3) negative family histories
should be defined more strictly, in order to compare families from
the top and bottom of the distribution, rather than the top and the
rest of the parental blood pressure distribution. The Bergen Blood
Pressure Study complies well with these guidelines. Families were
classified according to the blood pressures of both parents ob-
served over 27 years [4–8]. Only those families are taken into
account where both parents are concordantly either hypertensive
or normotensive (that is, HT/HT and NT/NT). The offspring of
these families have a very well documented genetic background of
essential hypertension and normotension.
The sympathetic nervous system is important to blood pressure
regulation through its affects on cardiac function, peripheral
vascular resistance, renin release, and renal sodium handling.
These regulatory systems, including the sympathetic nervous
system itself, are influenced by genetic variance [9, 10]. The
sympathetic nervous system, as reflected by catecholamine values,
has been implicated mechanistically in essential hypertension [11].
Thus, genes influencing catecholamine production, or genes in-
fluencing a-adrenoceptor and b-2 adrenoceptor function, are
potential candidate genes for hypertension. b-2 adrenoceptors
mediate vasodilation and impaired function of b-2 adrenoceptors
has been implicated in salt-sensitive hypertension in Europeans
[12]. This notion is supported by the observation that b-2 receptor
expression on cultured fibroblasts of normotensive white Europe-
ans with salt-sensitive blood pressure changes is less than half of
that observed in salt-resistant whites [13]. In African Americans,
isoproterenol-mediated vasodilation is impaired, compared to
whites [14]. A restriction fragment length polymorphism (RFLP)
in the b-2 adrenoceptor gene has recently been associated with
and linked to salt-sensitive hypertensive persons of African origin
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[15, 16]. These observations have generated great interest in the
b-2 adrenoceptor gene and its variations. We have established a
program to evaluate adrenergic receptors in hypertension. In the
present report we examined a b-2 receptor target region contain-
ing the promoter and the N-terminal of the gene for this molecule,
since variations in this region might explain differences in expres-
sion and receptor function.
METHODS
Subject groups
By means of data from population screening in 1963 to 1964
and a follow-up examination in 1990, we identified 23 married
couples where both spouses were hypertensive (blood pressures .
140/90 mm Hg) and 22 married couples where both spouses were
normotensive (blood pressures , 140/90 mm Hg) over 27 years of
observation [4, 5]. The hypertensive and normotensive families
had 54 and 55 offspring, respectively. These offspring form the
basis of this report [6–8]. Of the total 109 offspring, 82 partici-
pated. The protocol was approved by the University of Bergen’s
ethical committee, and written, informed consent was obtained
from all participants. The study was also approved by the Norwe-
gian state agency for data protection (Data-Tilsynet).
All procedures have been outlined in previous publications
[4–8]. Briefly, the subjects underwent a medical history and
physical examination. Anthropometric data were obtained. Twen-
ty-four-hour ambulatory blood pressure monitoring was per-
formed in the subjects. Accutracker II units (Suntech Medical
Instruments, Raleigh, NC, USA) were used. The monitor was
programmed to determine blood pressure at 20 minute intervals
from 06:00 to 22:59, and with 30 minute intervals from 23:00 until
05:59 the next morning. The daily sodium intake was estimated by
24-hour urine sodium excretion. The urine was examined for
sodium, potassium, chloride, and catecholamine (epinephrine and
norepinephrine) excretion. Blood samples were drawn for plasma
renin activity, aldosterone, and atrial natriuretic peptide concen-
trations. Autoanalyzer and radioimmunoassay methods are de-
scribed elsewhere [6–8]. The leukocytes from 64 of the subjects
were available for DNA extraction.
Molecular genetic analyses
The molecular genetic analyses described here are an integral
part of a “Multiplex PCR sequencing program” devoted to the
comprehensive evaluation of adrenergic receptor genes in hyper-
tension. Briefly, the principle of this method was to dissect the
candidate gene of interest into PCR fragments, which were then
pooled to perform multiplex sequencing reactions in one tube.
The resulting pools of termination reactions were loaded onto a
single gel lane, and resolved by size on a sequencing gel. The
sequencing ladders were transferred by direct transfer electro-
phoresis (DTE) onto a nylon membrane, and subsequently de-
coded by hybridizing the membrane sequentially with the appro-
priate, highly specific, oligonucleotide probes as many times as
there were DNA segments in the original pool. Thus, each
sequencing gel yielded a quantity of information equivalent to
that obtained from conventional reactions and gels, multiplied by
the number of PCR segments pooled. Image analysis relied on
“skilled pattern interpretation.” The termination reactions of a
given base were grouped into blocks of 12 individuals. Thus,
sequence differences could be identified by additional or missing
bands. In order to immediately test the b-2 adrenergic receptor
gene hypothesis outlined above, we chose to initially analyze the
target fragment containing the critical promoter region and the
N-teminal sequence, variations of which might possibly be asso-
ciated with altered receptor expression or down-regulation [13,
17].
The b-2 adrenergic receptor gene, its entire known regulatory
and coding region [18], Acc. No. J02960, was dissected into PCR
fragments of about 500 to 600 bp in size, using the DNASTAR
software (Lasergene). Genomic DNA was extracted from whole
blood according to the protocol outlined elsewhere [19] and PCR
amplified. Reaction mixtures contained 50 ng DNA, 0.2 mM of
each nucleoside triphosphate, 50 mM KOH (pH 9.2), 16 mM
(NH4)2SO4, 0.1% Tween 20 and 2 mM MgCl2, 30 mM of each
primer (59-GGGGAGGGAAAGGGGAGGAG-39 sense, and 59-
CTGCCAGGCCCATGA CCAGAT-39 antisense defined the
presented b-2 target region of 600 bp in size), 4 IU of a mix of a
Taq DNA Polymerase, Pyrococcus DNA Polymerase, and inor-
ganic pyrophosphatase from Thermus thermophilus. After initial
denaturation at 94°C for four minutes, polymerase chain reactions
(PCR) were held at 88°C for four minutes to allow a manual hot
start. Amplification was performed over 35 cycles at 94°C for 15
seconds, 67°C for 30 seconds, and 68°C for one minute. The
quality of amplification was verified by separating 5 ml of PCR
products on a 2% agarose gel and visualizing bands by ethidium
bromide and ultraviolet transillumination. The PCR products
were purified with QIAvac 96 (Quiagen).
Multiplex PCR sequencing was based upon a Thermosequenase
cycle sequencing protocol (Amersham). We applied the manufac-
turer’s conditions to perform four sequencing reactions simulta-
neously on four b-2 target segments. The termination products
were resolved on an ultrathin gel of 100 mm (5% acrylamide, 7 M
urea), transferred under standard DTE conditions [20] onto a
Biodyne A (Pall) membrane, which was cross-linked by ultraviolet
light. The membranes were hybridized with 32P-labeled, polyA-
tailed oligonucleotides as described earlier [21]. The probe to
detect the forward strand of the described 600 bp target segment
was: 59-CGAAGGGGCGAGGCACT-39, the probe to detect the
reverse strand was 59-CTTCACTGGCCTGTGCTG-39. Thus, se-
quence differences were validated by confirmatory sequencing of
the reverse strand. Sequence images were processed utilizing a
Phospho-Fluorimager (Storm 860, Molecular Dynamics). Images
were analyzed by “skilled pattern interpretation” independently
by two scientists, who were blind to individuals’ clinical diagnoses.
Any possible transcriptional relevance of DNA sequence differ-
ences identified in the promoter region was tested in a first pass
using SIGNAL SCAN Version 4.05 [21]. By means of this
program, we checked the variant sequence elements for homolo-
gies with published signal sequences contained in the following
three databases: Transcription Factor Database (TFD) Version
7.3, TRANSFAC and Information, and Matrix Database (IMD).
Genotypic sequence data were scored from digitalized images
independently by two expert readers. Consequently, data were
checked against the original images to control for input errors. All
results had been validated by complementary strand analysis, and
by two independent readings. Five individuals of each group were
selected randomly and completely genotyped independently for
confirmatory purposes. The results were a hundred percent
consistent.
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Statistical analysis
Differences between the offspring of the two groups were
analyzed by the two-sample Student’s t-test or the chi-square
statistic. Blood pressure and heart rate variables were entered in
a linear regression model with family history, gender, age, height,
and weight as independent variables. Since the two groups
differed significantly in age, adjustments were made in the multi-
variate analyses [4–8]. Statistical significance was accepted at P ,
0.05. Results are shown as mean 6 SD. Association and relative
risk analysis were done along the lines of the case control design,
where only the 16 first born available offspring of normotensive
parents were taken as the control group. They were then com-
pared to the 18 first born available offspring of the hypertensive
group. The global test of group 3 genotype independency was
done on 2 3 3 tables [cases vs. controls 3 genotypes (ww), (wp),
(pp); where w is wild-type and p is the polymorphic variant) by the
likelihood ratio chi square test (df 5 1). Subsequently, genotypes
were tested separately and combined (pp1wp) by 2 3 2 tables and
likelihood-ratio chi-square test as well as the relative risk statistics
(case-control odds-ratio with 95% confidence intervals). These
statistical methods were used as implemented in the program
package SAS version 6.04. We also performed an analysis of each
individual offspring’s blood pressure and heart rate values and the
genotypes. In this instance we performed the analysis not only
with the first-born offspring, but also with all the offspring.
Haplotype reconstruction and haplotype frequency estimates
for independent individuals were done by a maximum likelihood
procedure, as implemented in the computer program by Terwill-
iger and Ott termed EH. The full sample of typed individuals from
both groups was analyzed further by an interative procedure
suitable for pedigree data with the program ILINK from the
LINKAGE package developed by Terwilliger and Ott.
RESULTS
The clinical data from the two subject groups are described in
detail elsewhere [6–8]. Offspring of hypertensive families were on
average seven years older than offspring of normotensive families
(40 6 7 years compared to 33 6 6 years), whereas distributions of
gender and body mass index did not differ significantly between
groups. Office and average 24 hour ambulatory blood pressure
measurements were substantially higher in offspring of hyperten-
sive than normotensive families (P , 0.001), even after adjust-
ment for age and other covariates. Urine sodium and potassium
excretion were similar in both groups, suggesting similar daily
intakes. Also, offspring of hypertensive families excreted urine
catecholamines at higher rates than controls; however, differences
between groups were small and not statistically significant when
confounding variables were taken into account. Similarly, sug-
gested between-group contrasts in plasma renin activity disap-
peared after covariable adjustment. On the other hand, stratified
and multivariate analyses showed that offspring of hypertensive
families had lower baseline plasma atrial natriuretic peptide levels
than offspring of normotensive families. The groups were similar
with respect to serum aldosterone concentrations.
Image analysis in the b-2 target segment revealed four different
DNA sequence variants within this 600 bp region analyzed, two of
which were located in the promoter region at positions 247
(C3T) and 220 (T3C), and two in the n terminal of the
molecule at postions 146 (A3G) and 179 (C3G). Three base
substitutions at 249, 146, and 179, resulted in aminoacid
exchanges: Arg3Cys, Arg163Gly, and Gln273Glu. Statistical
evaluation of allele frequencies showed a significant increase of
allele Arg16 in first born offspring of hypertensive parents,
compared to first born offspring of normotensive parents (58% vs.
28%, P , 0.001), as shown in Table 1. In contrast, no significant
differences in allele frequencies between the groups could be
observed for the other polymorphisms. Accordingly, the global
test for genotypic associations (2 3 3 table, that is, group 3
genotype) were all nonsignificant except for the Arg163Gly
variation. None of the observed genotype distributions deviated
from those expected according to the Hardy-Weinberg equilib-
rium.
The haplotype distribution in hypertensive and normotensive
family offspring for the polymorphic and wild type alleles at the
four b-adrenoceptor gene sequence variants we examined is
shown in Table 2. We found that the leader cistron mutant with
the wild type alleles at the other loci was significantly more
frequent in offspring of hypertensive parents, compared to off-
spring of normotensive parents (P 5 0.042).
Table 1. Genotype distribution and allele frequencies of the b-2
adrenoceptor variants HT/HT are offspring of two hypertensive parents
and NT/NT are offspring of two normotensive parents
Base pair position
Genotype distribution Allele frequency
N w/w w/p p/p
P
valuea
w
(%)
p
(%)
P
valueb
Variant 1 HT/HT 18 3 5 10 30.6 69.4
247 C3T 0.569 0.260
NT/NT 16 4 6 6 43.7 56.3
Variant 2 HT/HT 18 9 6 3 66.7 33.3
220 T3C 0.730 0.378
NT/NT 16 6 6 4 56.2 43.8
Variant 3 HT/HT 18 7 7 4 58.3 41.7
46 A3G
(Arg163Gly
0.043 0.011
NT/NT 16 1 7 8 28.1 71.9
Variant 4 HT/HT 18 9 6 3 66.7 33.3
79 C3G
(Gln273Glu)
0.515 0.378
NT/NT 16 5 8 3 56.3 43.7
Abbreviations are: N, number; w, wild-type; p, polymorphism, defined
with reference to Kobilka et al [17], 1989, AccNo. J02960; base pair
positions defined relative to the translation initiation site.
a P values of the global, 2 3 3 test (likelihood ratio chi-square, df 5 1)
b P values of the allele frequency differences between groups, 2 3 2
table (likelihood ratio chi-square test)
Table 2. Haplotype distribution in HT/HT and NT/NT offspring
Haplotypes
A
wppw
B
wppp
C
pwww
D
pwpw
E
pwpp
F
pppw Sum
HT/HT 0 11 21 2 1 1 36
NT/NT 1 13 9 8 1 0 32
Sum 1 24 30 10 2 1 68
Frequency 1.5% 35.3% 44.0% 14.7% 3.0% 1.5%
The haplotypes were constructed from the alleles at loci 1, 2, 3, and 4
defined in Table 1. Chi-square 5 11.496, P 5 0.042. Abbreviations are:
w 5 wild-type; p, polymorphism.
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There is a significant association of group 3 genotype for the
Arg163Gly variant only. Details of this association are shown in
Table 3. The relative risk (RR, calculated as odds-ratio) conferred
by the Arg16 allele increased with gene dosage. The RR was 7.0
for Arg/Arg versus Arg/Gly, which was borderline significant (P 5
0.065). Comparing the genotype Arg/Arg to the combination
Gly/Gly and Arg/Gly yielded a relative risk of 9.55 (P 5 0.018).
Comparing the combination Arg/Gly and Arg/Arg to Gly/Gyl gave
a borderline RR of 3.5 (P 5 0.089). The highest RR was with the
genotypes Arg/Arg versus Gly/Gly (RR 5 14 with 95% confidence
limits 1.25 and 156.6; P 5 0.013). Thus, even with this relatively
small sample, the Arg16 variant showed a significant effect with a
recessive to semidominant mode of action.
Finally, we examined each individual offspring’s office and
24-hour blood pressure values in terms of his or her genotype
(Table 4). For all 61 subjects, a signficant effect of each genotype
on blood pressure was found for all four genotypes. A progressive
increase in blood pressure was observed comparing homozygote
wild-type, heterozygotes, and homozygote polymorphism-type.
The data suggest that all four polymorphisms are in linkage
disequilibrium. When we analyzed only the first-born offspring,
the results were similar and remained statistically signficant.
Comparing the blood pressures and heart rates of the offspring
documented the effect of having two hypertensive parents. Al-
though the blood pressures of the HT/HT offspring remained
within the “normal” range, their office blood pressures were 18/15
mm Hg higher and their ambulatory blood pressuers were 10/9
mm Hg higher than the NT/NT offspring. Their heart rates were
signficantly greater as well.
DISCUSSION
The unique quality of our particular subjects is the excellent
documentation of normotensive or hypertensive lineage by direct
blood pressure measurements in the parents over a period
spanning 27 years. Norwegians are not an isolated population as
such; however, the population has been quite stable. Thus, the
Bergen Blood Pressure Study should be uniquely suited to find
genes responsible for hypertension. However, as we have indi-
cated earlier [6–8], a familial predisposition to hypertension is not
identical with a genetic predisposition. Environmental factors may
be associated with both hypertension and the family history. The
phenotype in our study is not hypertension, but rather the state of
having two hypertensive parents (HT/HT) compared to two
normotensive parents (NT/NT). We cannot strictly classify our
HT/HT offspring as hypertensive, because they do not as yet meet
the arbitrary definition for that condition. Nevertheless, as cur-
rently young adults, the HT/HT offspring have blood pressures
that are 10 to 15% higher than NT/NT offspring. With this blood
pressure difference, we feel it is highly likely that the HT/HT
offspring will develop hypertension later in life. Phenotypization,
in terms of the renin-angiotensin-aldosterone axis, or circulating
catecholamines gave no immediate insight into hypertensive
mechanisms in our subjects. We selected the b-2 receptor gene
because of our interest stemming from earlier reports [12–14].
We identified four DNA sequence variants in this b-2 receptor
target region. Specifically, we discovered two novel sequence
differences in the promoter region. Of those, the 247 C3T
substitution causes an Arg3Cys exchange in the 59 leader cistron
of the gene, the peptide product of which in the b-2 adrenergic
receptor mRNA inhibits receptor synthesis. The 59 leader muta-
tions have been shown to affect receptor translations [22]. The
potential functional significance of this novel mutation remains to
be determined in vivo. However, we believe it is of interest that
our haplotype analysis revealed that a mutation at the 59 leader
cistron site and wild-type alleles at the other three locations was
more common in HT/HT compared to NT/NT offspring. The
second sequence difference found was obviously not contained
within critical regulatory motifs modulating gene expression, as
concluded from tests against the database for transcription regu-
latory factors. Another genetic variant was observed in the
N-terminal portion at position 179, resulting in a Gln273Glu
exchange, which has been shown to be functionally significant in
vitro [24]. Most importantly, these three variants were not associ-
ated with hypertension. In contrast, the Arg163Gly mutation
resulting from an exchange at base position 146 proved to be
important for a genetic propensity to hypertension. Offspring with
a family history of hypertension had an Arg16 allele frequency of
58%, compared to 28% for offspring without such a history. Our
relative risk analysis of the Gly/Gly, Arg/Gly, and Arg/Arg geno-
types showed a significant risk, comparing Arg/Arg to Gly/Gly and
significant risks comparing Arg/Arg to a combination of the other
two genotypes or a combination of the Arg-containing genotypes
to Gly/Gly. Since we confined ourselves to only the first born
offspring, our numbers are small. Nevertheless, they statistically
support the notion that the Arg-containing genotypes confer the
risk of hypertension in this northern European population. These
findings suggest a recessive gene action of the Arg16 variant, since
the heterozygous genotype Arg/Gly shows a minor relative risk,
contrasted with the homozygous Arg/Arg, when compared to the
wild-type Gly/Gly genotype. Hardy-Weinberg criteria were met
for both groups. Our findings underscore the importance of the
b-2 adrenoceptor gene locus as a susceptibility locus for hyper-
tension.
We genotyped all 64 offspring in the study. However, we
analyzed only the first-born offspring to search for associations of
our polymorphisms with the phenotypes HT/HT and NT/NT. We
took this precaution since siblings could have similar genotypes by
virtue of being related rather than by virtue of their parents’ blood
pressures. Nevertheless, when we analyzed each individuals’ blood
pressure in terms of his or her genotype, we found a highly
consistent and significant, step-wise effect of genotype on blood
pressure. This effect was true considering either all of the
offspring or just the first born. Furthermore, the effect was true
for all four genotypes, even though we identified an association
only with the Arg163Gly locus and parental blood pressure
Table 3. Influence on blood pressure of the Arg16 allele
Genotype Relative risk P value
1. Gly/Gly vs. Arg/Gly 2.0 (0.41–9.84) 0.39
2. Arg/Gly vs. Arg/Arg 7.00 (0.67–72.8) 0.065
3. Gly/Gly vs. Arg/Arg 14.00 (1.25–156.6) 0.013
4. Gly/Gly 1 Arg/Gly vs.Arg/Arg 9.55 (1.02–89.2) .018
6. Gly/Gly vs. Arg/Gly 1 Arg/Arg 3.5 (0.79–15.4) 0.089
The relative risks (RR) of the Gly/Gly, Arg/Gly, and Arg/Arg genotype
comparisons and their 95% confidence limits are given. Statistical com-
parisons are given between the various alleles and combinations of the
alleles. The P value of the likelihood ratio, chi-square test, 2 3 2 table,
df 5 1.
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status. The data suggest that the other genotypes are in linkage
dysequilibrium with the Arg163Gly locus.
The b-2 adrenoceptor is a member of the guanosine-protein
linked, seven member spanning domain receptor family and has
been extensively studied [24]. An amino terminal variant in the
b-2 adrenoceptor, which encodes glycine instead of arginine at
basepair position 46 (Arg163Gly), has been described which
appears to have functional significance. Reihsaus et al transfected
Chinese hamster fibroblasts with both b-2 adrenoceptor variants
[25]. The variants showed equal affinity for epinephrine or
isoproterenol; however, the Gly16 variant exhibited increased
down-regulation in response to isoproterenol, compared to the
Arg16 variant [26]. Such a down-regulation pattern could lead to
impaired vasodilatory responses to circulating b-2 adrenergic
agonists. This hypothesis is supported by in vivo studies showing
that pulmonary b-2 adrenoceptors with the Gly16 variant also
exhibit increased down-regulation in response to salbutamol,
compared to the Arg16 variant [24]. Furthermore, a recent report
indicating that the Gly16 variant in the b-2 adrenoceptor is
associated with nocturnal asthma further supports the notion that
this polymorphism may have major functional importance [27].
Finally, increased b-2 adrenoceptor down-regulation might serve
to explain the decreased b-2 adrenoreceptor expression on the
fibroblasts of salt-sensitive, compared to salt-resistant normoten-
sive Europeans [13].
Svetkey et al used an restriction fragment length polymorphism
(RFLP) in the b-2 adrenoceptor gene and showed that a variant
of this RFLP was associated with hypertension in African Amer-
icans [15]. More recently, they used the same RFLP in a study of
20 black families with 109 sib-pairs [17]. They were able to show
significant linkage of the b-2 adrenoceptor locus with diastolic
blood pressure salt-sensitivity. Salt-sensitivity was defined as the
difference between diastolic blood pressure after volume expan-
sion, compared to diastolic blood pressure after volume contrac-
tion [28]. The linkage remained significant after correction for
various confounders. It is likely that the RFLPs used by Svetkey et
al [15, 16] are in linkage disequilibrium with the Arg163Gly16
coding alteration, although that possibility has not been shown for
certain.
Svetkey et al directed their attention at salt sensitive persons of
African heritage [15, 16]. A host of literature is directed at ethnic
differences between blacks and whites, which are presumably
primarily of genetic origin [29, 30]. American blacks are a group
purported to be highly salt-sensitive [31]. Salt sensitivity has been
attributed to an up-regulated a-adrenoceptor and/or an increased
tendency to down-regulate the b-2 adrenoceptor in response to a
high salt intake [12]. Recently, Kotanko et al performed an
association study in 136 African Caribbeans with hypertension
and 81 unrelated control persons from the island of St. Vincent
[32]. They found significant support for the prodown-regulatory
Gly16 variant with hypertension. These hypertensive persons of
African origin would be expected to be salt sensitive, although
they were not tested.
Thus, we might have expected that the Gly16 variant would be
associated with a propensity for hypertension rather than the
Arg16 variant. The Bergen offspring were not subjected to a
protocol directed at examining salt sensitivity. The Bergen hyper-
tensive family history offspring may all be salt resistant. The salt
excretion of the two groups was not elucidative; both groups
excreted similar amounts of sodium over 24 hours in their urine
[7]. A specific test for salt-sensitivity was not performed. However,
against salt-resistance is the fact that plasma renin activity tended
to be lower in the hypertensive family-history offspring compared
to controls, and that atrial natriuretic peptide values were lower,
even though other variables would have predicted higher atrial
natriuretic peptide values [8]. These observations are admittedly
circumstantial, but are more consistent with salt-sensitivity than
salt-resistance. Finally, if the Gly16 variant is indeed associated
with a greater tendency for the b-adrenoceptor to down-regulate,
those with this variant (the offspring of normotensive parents in
our study) could behave as if they had relative b-blockade,
compared to those carrying the Arg16 variant. As with the
b-blockers, which very effectively lower blood pressure, the Gly16
variant may engender cardiac relaxing effects, a less activated
Table 4. An analysis of systolic and diastolic blood pressure (mm Hg) and genotype (w, wild-type; p, polymorphism) for each individual offspring
Genotype
Systolic BP Diastolic BP
ww wp pp P value ww wp pp P value
All subjects (N 5 61)
247 C3T 117 6 10 124 6 15 132 6 17 0.01 70 6 8 76 6 12 80 6 12 0.05
220 T3C 132 6 17 125 6 15 117 6 10 0.01 80 6 12 76 6 11 70 6 8 0.05
46 A3G 140 6 18 126 6 14 116 6 9 0.01 86 6 13 77 6 11 70 6 8 0.01
79 C3G 133 6 17 122 6 15 119 6 10 0.01 81 6 12 75 6 10 70 6 9 0.05
Oldest offspring in each family
(N 5 34)
247 C3T 116 6 11 129 6 16 135 6 20 0.05 70 6 11 78 6 12 81 6 14 0.05
220 T3C 133 6 19 132 6 8 116 6 11 0.05 80 6 14 79 6 13 70 6 11 0.05
46 A3G 144 6 17 133 6 16 115 6 10 0.01 88 6 13 79 6 12 69 6 9 0.01
79 C3G 136 6 20 127 6 16 118 6 12 0.05 83 6 14 76 6 11 70 6 12 0.05
Blood pressure (mm Hg) and
heart rate (bpm) of all
offspring by family history NT/NT HT/HT P value
Office systolic BP 116 6 10 134 6 15 0.01
Office diastolic BP 68 6 6 83 6 11 0.01
Office HR 70 6 14 75 6 11 n.s.
24-hr Systolic BP 112 6 8 122 6 10 0.01
24-hr Diastolic BP 65 6 5 74 6 6 0.01
24-hr HR 68 6 10 75 6 9 0.01
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renin-angiotensin system, and an altered control of the sympa-
thetic nervous system at the level of the central nervous system.
The latter has been associated with a change in baroreceptor
sensitivity, an alteration in peripheral adrenergic neuron function,
and an increase in prostacyclin biosynthesis.
Conceivably, the advantage or disadvantage of the
Arg163Gly16 variant could be a function of the genetic back-
ground in which it is found. In summary, an analysis of the Bergen
Blood Pressure Study underscores the fact that the b-2 adreno-
ceptor is a susceptibility locus for hypertension. Interestingly, the
distribution of the Arg163Gly16 variant in our subjects is
opposite to what might be expected in salt sensitive hypertension
[12, 13]. We have no reason to believe that our findings are the
result of an artifact related to family suggestion; however, we are
cautious in our interpretations and underscore the importance of
verification in additional studies. A mechanistic explanation for
our findings may be important to elucidate mechanisms relevant
to the development of essential hypertension.
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